|
Patent landscape, scope, and claims: |
United States Patent 4,959,366 Scope, Claim Coverage, and US Patent Landscape Analysis
US Patent 4,959,366 claims a narrow, structurally defined small-molecule “compound of formula” estate with downstream coverage to specific substituted variants, plus two functional end-use layers: pharmaceutical composition and method-of-treatment for cardiac arrhythmia. The claim set is dominated by genus-to-subgenus formula language (Ra/Rb, Y linker, alk length, X = O or S) and then narrows via enumerated substitution constraints (C1–C4 alkyl/halo/CF3, sulfonamide and amide/N-substituted heterocyclic amines). Claims 1–6 plus 7–22 define the core substitution pattern; claims 22–42 add explicit R2 embodiments; claims 43–45 add specific R3 instances; claims 46–48 add a composition and method-of-use layer with a cardiac arrhythmia therapeutic frame.
What are the key claim scope drivers in US Patent 4,959,366 (compound-of-formula genus)?
Immediate claim architecture
- Independent claim anchors (compound-of-formula):
- Claim 1: compound of Formula I with Ra/Rb split logic, and defined positions for X (O or S absent), Y (ethylene optionally methyl-substituted), “alk” (ethylene/trimethylene/tetramethylene optionally methyl-substituted), R (C1–C4 alkyl), and R2 (H, halo, CF3, or C1–C4 alkyl).
- Claim 2: compound of Formula II with both R and R1 independently C1–C4 alkyl, X (O or S absent), Y (ethylene optionally methyl-substituted), “alk” (ethylene/trimethylene/tetramethylene optionally methyl-substituted), R2 (H, halo, CF or C1–C4 alkyl), and R3 as either sulfonamide (NHSO2 C1–C4 alkyl) or amide (CONR4R5 with R4/R5 H or C1–C4 alkyl; or together with N to form pyrrolidinyl, piperidino, morpholino, N-methylpiperazin-1-yl).
- Dependent claims (narrowing knobs): 3–6 (R1 methyl; R methyl/ethyl), 7–11 (X = O), 12–21 (Y = —(CH2)2—), 22–41 (R2 = H/Cl/CH3 enumerations), 42 (R2 = H), 43–44 (R3 specific: NHSO2 CH3; amide variants), 45 (another enumerated compound of a specific structure), 46 (Y = —(CH2)2— and X = O), 47–48 (composition and method-of-use).
How do Ra/Rb constraints in Claim 1 limit coverage?
Claim 1 contains a mutual exclusivity constraint:
- Ra can be —NO2, —NH2, or —NHSO2 R1 (where R1 is C1–C4 alkyl).
- Rb can be —NO2, —NH2, or one of:
- —NHSO2 (C1–C4 alkyl), or
- —CONR4R5 where R4/R5 each H or C1–C4 alkyl, or R4/R5 taken together with N gives a ring amine (1-pyrrolidinyl, piperidino, morpholino, or N-methylpiperazin-1-yl).
- Proviso: “when one of Ra and Rb is —NO2, then the other is not —NH2.”
- This is a hard structural exclusion that prevents simultaneous (—NO2, —NH2) pairing across the Ra/Rb positions.
What substitution freedom remains in Claim 2?
Claim 2 removes the Ra/Rb mutual-exclusion architecture and instead sets:
- R and R1 independently C1–C4 alkyl
- R2 includes H, halo, CF, or C1–C4 alkyl (note CF without subscript “3” in the claim text as provided)
- R3 is limited to either:
- sulfonamide NHSO2(C1–C4 alkyl), or
- amide CON(R4)(R5) with H/C1–C4 alkyl or ring-forming cyclic amines (pyrrolidinyl, piperidino, morpholino, N-methylpiperazin-1-yl).
Where are the “hot spots” that typically determine infringement and design-around risk?
- X (oxygen vs sulfur absent): Claim 7–11 explicitly sets X = O for a sub-range.
- Y linker: Claim 12–21 and Claim 46 lock Y to —(CH2)2— (ethylene unit form).
- “alk” length: Claim 1/2 define “alk” as ethylene, trimethylene, or tetramethylene with optional methyl substitution; this governs the distance between key scaffold elements.
- R2 enumeration: Claims 22–41 narrow R2 to H, Cl, CH3, which is often where competitors try to land.
- R3 functional group type: sulfonamide vs amide vs cyclic secondary/tertiary amine at the terminal group. This is a frequent design-around vector.
What exact chemical ranges are covered (R2 and Y/alk/X limitations)?
R2 in Claims 22–42: the enumerated boundary layer
Claims 22–41 progressively refine R2 to H, Cl, or CH3, and Claim 42 limits further to H only.
- Claim 22–41: For each dependency, R2 is restricted to H, Cl, or CH3.
- Claim 42: R2 = H.
- Claim 2 base (genus): R2 = H, halo, CF, or C1–C4 alkyl.
Practical reading: even if R2 is broader in Claim 2, the dependent set creates a strong evidentiary hook for infringement arguments when R2 is limited to the common Cl/Me/H pattern.
Y in Claims 12–21 and Claim 46
- Claims 12–21: Y is —(CH2)2— across multiple dependent layers.
- Claim 46: combines Y = —(CH2)2— with X = O or S (and Y/X are central “shape” constraints).
X in Claims 7–11 and Claim 46
- Claims 7–11: X = O.
- Claim 46: X is O or S, and Y = —(CH2)2—.
Practical reading: If an accused compound flips X to S, it can evade the X=O dependent layer but may still fall within the broader genuses (Claim 1/2) depending on the “X is O or S absent” phrasing in the claim text you provided.
Which embodiments are explicitly called out (R3 variants and the “compound of claim 45” structure)?
R3 variants in Claims 43–44
Claim 43 specifies R3 as one of multiple defined structures:
- —NHSO2 CH3
- —CONH2
- CON(C2H5)2
- and a further structure shown as ##STR75## (exact chemistry not reproduced in the provided text beyond placeholder).
Claim 44 narrows:
Claim 45
Claim 45 is “A compound of the formula: ##STR76##” which is an additional specific structure instance not fully enumerated in the text you supplied (only as an image placeholder). From a landscape perspective, this typically:
- locks at least one commercially relevant example or a preferred embodiment into the claims independent from the broad genus, and
- improves enforceability by reducing ambiguity in claim construction for the terminal substituent pattern.
What downstream protection exists for formulations and cardiac arrhythmia use?
Pharmaceutical composition (Claim 47)
- “A pharmaceutical composition comprising an anti-arrhythmic effective amount” of a compound of Claim 2, plus a pharmaceutically acceptable diluent or carrier.
Scope effect: This is a use-driven formulation claim tied to Claim 2 compound coverage. It is not a process claim and does not claim excipient novelty by itself; the hook is the active compound (Claim 2 scope).
Method-of-treatment (Claim 48)
- “A method of treating cardiac arrhythmia” by administering to an “arrhythmic host” an anti-arrhythmic effective dose of a compound of Claim 2, with diluent/carrier.
Scope effect: This is a classic medical use claim. It typically impacts:
- direct infringement by physicians prescribing within the claimed therapeutic frame (jurisdiction dependent),
- and the strength of arguments in Hatch-Waxman type litigation against parties whose product labels and marketing are tied to cardiac arrhythmia.
How strong is the patent estate for a “compound-of-formula” strategy (what is likely broad vs narrow)?
Broad elements
- Genus formula coverage (Claims 1–2) with:
- flexible alkyl sizes (C1–C4),
- linker length variations (ethylene/trimethylene/tetramethylene; optionally methyl-substituted),
- oxygen vs sulfur option in the core scaffold (as written).
Narrow elements
- Functional substituent types limited to specific nitrogen-containing groups:
- Ra/Rb set in Claim 1 (NO2, NH2, sulfonamide with C1–C4 alkyl; or amide with H/C1–C4 alkyl or cyclic amines).
- Dependent claim narrowing to common medicinal chemistry motifs:
- X=O and Y=—(CH2)2—,
- R2 confined to H/Cl/CH3,
- R3 confined to specific sulfonamide and amide embodiments.
Landscape implication: a competitor can attempt to evade by changing:
- the terminal nitrogen chemistry (R3),
- the presence/position of X,
- the linker length (“alk”) or Y unit,
- or the R2 substituent set.
But because the independent claims already include multiple degrees of freedom, the estate is more difficult to design around than a purely numeric series would be. The real leverage is where a competitor’s structure lands within the same “hot spot” constraints (X, Y, R2 set, and R3 type).
What generic entry risks exist under this patent (and what would trigger infringement)?
Key infringement triggers under typical US claim construction
- A generic or new entrant would face risk if its ANDA/NDA product contains an active compound that:
- matches the compound-of-formula limitations of Claim 1 or Claim 2 (and its dependent narrower variants), and/or
- if labeling and use correspond to cardiac arrhythmia dosing under Claim 48, and
- if the product formulation is simply a standard pharmaceutically acceptable carrier with an “anti-arrhythmic effective amount” per Claim 47 (formulation typically won’t avoid this unless the active falls outside Claim 2).
Most likely litigation focal points
- Whether the competitor’s compound matches R2 (H vs Cl vs CH3 vs halo/CF vs other halogens),
- Whether X is O vs S (and how “absent” is interpreted),
- Whether Y equals —(CH2)2—,
- Whether the terminal group is sulfonamide vs amide vs cyclic amine (R3 definition).
What patent landscape coverage exists beyond this single patent number?
Based strictly on the information provided in the prompt, only the content of US Patent 4,959,366 (claims 1–48) is available. No priority data, prosecution history, specification details, assignee, family members, continuation/divisional status, related US patents, or FDA/Orange Book listing are provided here. Without those, a complete, accurate “landscape” across other US patents, jurisdictions, or Orange Book entries cannot be produced from the supplied inputs.
Key Takeaways
- US 4,959,366 is a structural small-molecule patent built around two independent compound-of-formula claims (Claims 1 and 2) that constrain scaffold features (X, Y, “alk”), substitution ranges (R, R1, R2), and terminal nitrogen chemistry (Ra/Rb in Claim 1; R3 in Claim 2).
- Dependent claims sharply narrow to:
- X = O (Claims 7–11),
- Y = —(CH2)2— (Claims 12–21, Claim 46),
- R2 = H/Cl/CH3 (Claims 22–41) and R2 = H (Claim 42),
- specific R3 embodiments including NHSO2 CH3 and defined amides (Claims 43–44).
- The estate extends protection into commercially relevant end points:
- pharmaceutical composition (Claim 47) and
- method of treating cardiac arrhythmia (Claim 48) tied to Claim 2 compounds.
- In competitive design-around and generic risk analysis, the most actionable “avoidance levers” are the terminal N group (R3), X (O vs S), linker lengths (Y and “alk”), and R2.
FAQs
-
Can a compound outside R2 = H/Cl/CH3 still infringe?
Yes if it remains within the broader R2 definition in the independent claim (Claim 1/2), since the H/Cl/CH3 set in dependent claims is a narrowing, not an absolute restriction on the independent scope.
-
Does changing sulfonamide to amide avoid coverage?
It can, depending on whether the substituted terminal group still fits the R3 definitions in Claim 2 (sulfonamide or amide with the specified R4/R5 limits or ring-forming cyclic amines).
-
Is X = O a hard requirement for all coverage?
No. X = O is in dependent claims (Claims 7–11). Independent claims include X as a broader choice (as written in the claim text you provided). Avoiding dependent coverage does not necessarily avoid independent coverage.
-
Do the composition and method claims require a specific formulation technology?
No. Claim 47 is a standard composition with pharmaceutically acceptable diluent/carrier, and Claim 48 is a standard therapeutic dosing method with an anti-arrhythmic effective dose.
-
What is the most litigation-prone ambiguity point in this claim set?
The claim-language phrasing around X being “O or S absent” and the placeholders for ##STR75## and ##STR76## typically concentrate claim-construction disputes around how the specification images map into the legal claim boundaries.
More… ↓
⤷ Start Trial
|
